Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

研究方向

Immunology/Inflammation 相关产品(4245)

  • GC72114 structure
    GC72114Pam2CSK4 TFA
    纯度: >99.00%

    Pam2CSK4 TFA是一种脂肽,是一种不依赖tlr6的TLR2配体和激动剂。

  • GC72139 structure
    GC72139Peptide5 TFA
    纯度: 不显示

    Peptide5 TFA,一种连接蛋白43模拟肽,减少脊髓损伤后动物肿胀、星形胶质增生和神经元细胞死亡。

  • GC72142 structure
    GC72142PSMα3
    CAS: 1001405-52-2
    纯度: >98.00%

    PSMα3是一种肽,用于操纵DC成为DC疫苗接种策略的耐受性。

  • GC72183 structure
    GC72183[D-Leu-4]-OB3
    CAS: 289056-32-2
    纯度: >99.00%

    [D-Leu-4]-OB3抑制促炎、增殖和转移基因的表达以及pd - l1的表达。

  • GC72186 structure
    GC72186WLSEAGPVVTVRALRGTGSW
    CAS: 771479-86-8
    纯度: >96.00%

    WLSEAGPVVTVRALRGTGSW是一种心肌细胞特异性肽。

  • GC72187 structure
    GC72187Erepdekinra
    CAS: 2641313-47-3
    纯度: >98.50%

    Erepdekinra是一种白细胞介素- 17a (IL-17A)受体拮抗剂。

  • GC72216 structure
    GC72216(Gly14)-Humanin (human) (acetate)
    纯度: >98.00%

    (Gly14)-Humanin (human) (acetate)是Humanin的类似物,其中第14个氨基酸丝氨酸被甘氨酸(Gly)取代。

  • GC72251 structure
    GC72251Tripeptide-32
    CAS: 1185583-20-3
    纯度: >99.00%

    Tripeptide-32是一种具有抗衰老作用的生物活性肽,已被报道用作化妆品成分。

  • GC72284 structure
    GC72284M-TriDAP
    CAS: 60230-21-9
    纯度: 不显示

    M-TriDAP(N-乙酰胞壁酰-L-Ala-γ-D-Glu-meso-di氨基庚酸)是一种NOD1/2激动剂和生物活性肽。

  • GC72306 structure
    GC72306Lib2-1
    CAS: 2983116-47-6
    纯度: >99.00%

    Lib2-1大环肽是IL-17C/IL-17RE相互作用抑制剂。

  • GC72319 structure
    GC72319Atrosab
    CAS: 1365659-05-7
    纯度: >96.00%

    Atrosab是一种人源化IgG1拮抗性抗TNFR1抗体。

  • GC72320 structure
    GC72320Temtokibart
    CAS: 2639874-57-8
    纯度: >99.00%

    Temtokibart是一种针对IL22RA1的人源化IgG1λ2抗体。

  • GC72324 structure
    GC72324Dazukibart
    CAS: 2639474-65-8
    纯度: >99.00%

    Dazukibart是一种小鼠来源的人源化IgG1κ抗体,靶向干扰素β 1 (IFNB1)。

  • GC72326 structure
    GC72326Riliprubart
    CAS: 2756228-76-7
    纯度: >99.00%

    Riliprubart(SAR445088)是一种抗C1s人源化单克隆抗体,可抑制经典补体系统近端部分的活化C1s。

  • GC72327 structure
    GC72327Stapokibart
    CAS: 2734715-10-5
    纯度: >96.00%

    Stapokibart(CM310)是一种靶向IL-4Rα的人源化单克隆抗体,可有效阻断细胞因子IL-4和IL-13与其共受体亚基IL-4Rα之间的相互作用。

  • GC72340 structure
    GC72340Enokizumab
    CAS: 909875-08-7
    纯度: >99.00%

    Enokizumab(MEDI-528)是一种针对白细胞介素(IL)-9的单克隆抗体。

  • GC72345 structure
    GC72345Tildrakizumab
    CAS: 1326244-10-3
    纯度: >95.00%

    Tildrakizumab(SCH 900222)是一种人源化抗IL-23(p19亚基)单克隆抗体。

  • GC72352 structure
    GC72352Fontolizumab
    CAS: 326859-36-3
    纯度: >97.00%

    Fontolizumab(HuZAF)是一种人源化单克隆抗IFN-γ抗体。

  • GC72354 structure
    GC72354Lampalizumab
    CAS: 1278466-20-8
    纯度: >99.00%

    Lampalizumab (RG 7417)是一种人源化单克隆抗体,靶向补体因子D的替代补体途径。

  • GC72358 structure
    GC72358Perakizumab
    CAS: 89957-37-9
    纯度: >99.00%

    Perakizumab (RG4934)是一种人源化抗IL-17A (Interleukin Related)的IgG1κ单克隆抗体。

  • GC72359 structure
    GC72359Quilizumab
    CAS: 1228538-47-3
    纯度: >96.00%

    Quilizumab(抗人NGcGM3重组抗体)是一种人源化IgG1κ单克隆抗体。

  • GC72363 structure
    GC72363Timolumab
    CAS: 1073538-99-4
    纯度: >98.00%

    Timolumab(BTT1023),一种特异性结合VAP-1的重组全人单克隆抗体。

  • GC72365 structure
    GC72365Visilizumab
    CAS: 219716-33-3
    纯度: >98.00%

    Visilizumab(抗人CD3E重组抗体)是一种人源化低Fc受体结合的抗CD3单克隆IgG2抗体。

  • GC72367 structure
    GC72367Vunakizumab
    CAS: 1792181-33-9
    纯度: 95.00%

    Vunakizumab(抗人IL17A重组抗体)是一种重组人IgGκ单克隆抗体,靶向IL-17A并抑制其与IL-17受体的相互作用。